BR9916063A - Composições auto-emulsificantes para medicamentos fracamente solúveis em água - Google Patents

Composições auto-emulsificantes para medicamentos fracamente solúveis em água

Info

Publication number
BR9916063A
BR9916063A BR9916063-3A BR9916063A BR9916063A BR 9916063 A BR9916063 A BR 9916063A BR 9916063 A BR9916063 A BR 9916063A BR 9916063 A BR9916063 A BR 9916063A
Authority
BR
Brazil
Prior art keywords
self
emulsifying compositions
poorly water
effective amount
propylene glycol
Prior art date
Application number
BR9916063-3A
Other languages
English (en)
Inventor
Nirmal Mulye
Original Assignee
Pharmasolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasolutions Inc filed Critical Pharmasolutions Inc
Publication of BR9916063A publication Critical patent/BR9916063A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçõES AUTO-EMULSIFICANTES PARA MEDICAMENTOS FRACAMENTE SOLúVEIS EM áGUA". A presente invenção é dirigida a uma composição farmacêutica compreendendo uma quantidade farmaceuticamente eficaz de um medicamento lipofílico, em associação com um veículo farmacêutico, o veículo compreendendo um medicamento lipofílico solubilizando uma quantidade eficaz de um monoéster de propileno glicol de ácido graxo C~ 6~-C~ 18~ possuindo pelo menos 60% em peso de monoéster, com base no peso total de éster propileno glicol e um tensoativo não-iónico.
BR9916063-3A 1998-12-11 1999-12-10 Composições auto-emulsificantes para medicamentos fracamente solúveis em água BR9916063A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11195198P 1998-12-11 1998-12-11
PCT/US1999/029373 WO2000033862A1 (en) 1998-12-11 1999-12-10 Self-emulsifying compositions for drugs poorly soluble in water

Publications (1)

Publication Number Publication Date
BR9916063A true BR9916063A (pt) 2002-01-22

Family

ID=22341327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916063-3A BR9916063A (pt) 1998-12-11 1999-12-10 Composições auto-emulsificantes para medicamentos fracamente solúveis em água

Country Status (15)

Country Link
US (2) US6638522B1 (pt)
EP (1) EP1135150B1 (pt)
JP (1) JP2002531515A (pt)
KR (1) KR100602725B1 (pt)
CN (1) CN1236813C (pt)
AU (1) AU775523B2 (pt)
BR (1) BR9916063A (pt)
CA (1) CA2354233A1 (pt)
IL (2) IL143580A0 (pt)
MX (1) MXPA01005884A (pt)
NZ (1) NZ512287A (pt)
PL (1) PL348193A1 (pt)
RU (1) RU2257917C2 (pt)
WO (1) WO2000033862A1 (pt)
ZA (1) ZA200104585B (pt)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362573A (en) * 2000-05-25 2001-11-28 Cipla Ltd Cyclosporin formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) * 2001-01-18 2004-12-02 Upjohn Co Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
AUPR573001A0 (en) * 2001-06-15 2001-07-12 Glaxo Wellcome Australia Ltd Lymphatic drug delivery system
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
WO2003053404A1 (en) * 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040142040A1 (en) * 2002-10-31 2004-07-22 Dong Liang C. Formulation and dosage form providing increased bioavailability of hydrophobic drugs
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
KR20040047056A (ko) * 2002-11-29 2004-06-05 한미약품 주식회사 비페닐디메틸디카복실레이트의 경구용 마이크로에멀젼조성물
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
WO2004065561A2 (en) 2003-01-21 2004-08-05 Ptc Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8473399B2 (en) * 2003-03-04 2013-06-25 Siebel Systems, Inc. Invoice data object for a common data object format
WO2004084870A1 (en) * 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2533013C (en) * 2003-07-17 2011-07-26 Banner Pharmacaps, Inc. Controlled release preparations
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
JP2007504826A (ja) * 2003-09-09 2007-03-08 スリーエム イノベイティブ プロパティズ カンパニー 濃厚な抗菌性組成物および方法
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20050053593A1 (en) * 2003-09-09 2005-03-10 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005037251A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self-emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005037250A1 (en) * 2003-10-17 2005-04-28 Amylin Pharmaceuticals, Inc. Self emulsifying drug delivery systems for hydrophobic therapeutic compounds
WO2005049868A1 (en) * 2003-11-17 2005-06-02 Pct Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating her2 expression
AR046773A1 (es) * 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
GB2429916A (en) * 2004-06-07 2007-03-14 Strides Arcolab Ltd Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
RU2007123366A (ru) * 2004-11-24 2008-12-27 Мерк Энд Ко. Жидкие и полутвердые фармацевтические препаративные формы для перорального введения замещенного амида
CN1660064B (zh) * 2004-12-28 2010-09-29 中山大学 那格列奈自乳化释药系统
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) * 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
AU2006213673A1 (en) * 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
US20060204452A1 (en) * 2005-03-10 2006-09-14 Velamakanni Bhaskar V Antimicrobial film-forming dental compositions and methods
TW200724134A (en) 2005-03-10 2007-07-01 3M Innovative Properties Co Antimicrobial compositions and methods
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
WO2006099232A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
BRPI0709606B8 (pt) 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
CN100408025C (zh) * 2006-11-24 2008-08-06 上海医药(集团)有限公司 倍他米松β-11物的自乳化组合物及其制备方法和应用
CA2683407C (en) 2007-04-04 2016-09-20 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
JP2010527285A (ja) 2007-04-26 2010-08-12 シグモイド・ファーマ・リミテッド 複数のミニカプセルの製造
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
CN101513395B (zh) * 2008-02-20 2011-01-12 单宝华 紫杉醇类双层软胶囊口服制剂药物
WO2010117873A2 (en) * 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
WO2010133609A2 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
EP2437725A4 (en) 2009-06-05 2014-02-26 Sunev Pharma Solution Ltd TOPICAL MICROEMULSIONS FOR THE TREATMENT OF RHEUMATIC SUFFERINGS
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
CN101756900B (zh) * 2010-02-25 2012-05-30 谢恬 一种榄香烯微乳
CN102970990A (zh) 2010-05-03 2013-03-13 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
CN102000026A (zh) * 2010-10-25 2011-04-06 徐州医学院 一种萘普生口服微乳制剂及其制备方法
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
WO2013137694A1 (ko) * 2012-03-16 2013-09-19 한국콜마 주식회사 직쇄 알킬체인을 가진 지방산을 포함하는 무수무복계면물질
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP2884961B1 (en) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidate extended release chewable tablet
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
AU2013346501B2 (en) 2012-11-19 2017-07-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors
JP6192244B2 (ja) 2013-01-22 2017-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改良されたバイオアベイラビリティを有する薬学的組成物
WO2014128564A2 (en) 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
DK3091860T3 (en) * 2013-08-29 2019-04-29 Abbott Lab NUTRITIONAL COMPOSITION WITH LIPOFILE RELATIONSHIPS WITH IMPROVED SOLVENCY AND BIOTAILABILITY
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
BR112017009510A2 (pt) 2014-11-07 2017-12-19 Sigmoid Pharma Ltd composições compreendendo ciclosporina
EP3302429A1 (en) 2015-05-28 2018-04-11 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445174B (sv) 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
FR2502951B1 (fr) * 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
CH653256A5 (en) * 1981-04-06 1985-12-31 Sandoz Ag Microemulsion for cutaneous use
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
GB8630273D0 (en) * 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5154930A (en) 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
ES2033086T3 (es) 1988-01-29 1993-03-01 Sankyo Company Limited Un procedimiento para la preparacion de una composicion farmaceutica.
CH679119A5 (pt) 1988-05-13 1991-12-31 Sandoz Ag
US4918103A (en) * 1988-07-25 1990-04-17 Formulations Development Labs Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
DE4004614A1 (de) 1990-02-15 1991-08-22 Basf Ag Verfahren zur uebertragung von bichromophoren cyanogruppen enthaltenden methinfarbstoffen
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
JPH06511419A (ja) * 1990-06-08 1994-12-22 アフィニティー　バイオテック，インコーポレイテッド ミクロエマルジョンを製造する方法
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JPH06157294A (ja) 1992-11-19 1994-06-03 Tanabe Seiyaku Co Ltd 脂肪微粒子製剤
ES2204919T3 (es) 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
CA2185803C (en) * 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5583153A (en) * 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
SE504582C2 (sv) * 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
KR0183449B1 (ko) 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
FR2753626B1 (fr) * 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
HU228855B1 (en) 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
CH688504A5 (de) * 1997-03-26 1997-10-31 Marigen Sa Ultramikroemulsionen aus spontan dispergierbaren Konzentraten mit antitumoral wirksamem Taxol und mit Taxol-analogen Verbindungen.
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) * 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
ID25908A (id) * 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
ES2215277T3 (es) * 1998-08-18 2004-10-01 Panacea Biotec Limited Composicion de ciclosporina que comprende un vehiculo hidrofilo.
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
PL348193A1 (en) 2002-05-06
IL143580A (en) 2007-05-15
US6436430B1 (en) 2002-08-20
RU2257917C2 (ru) 2005-08-10
JP2002531515A (ja) 2002-09-24
CA2354233A1 (en) 2000-06-15
EP1135150A4 (en) 2006-05-17
CN1236813C (zh) 2006-01-18
WO2000033862A1 (en) 2000-06-15
US6638522B1 (en) 2003-10-28
AU2588500A (en) 2000-06-26
EP1135150A1 (en) 2001-09-26
ZA200104585B (en) 2002-06-13
KR20010093154A (ko) 2001-10-27
MXPA01005884A (es) 2002-04-24
IL143580A0 (en) 2002-04-21
AU775523B2 (en) 2004-08-05
NZ512287A (en) 2002-12-20
EP1135150B1 (en) 2012-10-17
KR100602725B1 (ko) 2006-07-20
CN1338942A (zh) 2002-03-06

Similar Documents

Publication Publication Date Title
BR9916063A (pt) Composições auto-emulsificantes para medicamentos fracamente solúveis em água
BR0011772A (pt) Conjugado de droga-oligÈmero, composição farmacêutica, método de solubilização de uma droga em uma microemulsão, e, métodos para fornecer um conjugado de droga ativa - hidrófilo e um conjugado de droga ativa - peg a um sìtio de um indivìduo
PT1033981E (pt) Formulacoes e metodos para reduzir a toxicidade de agentes antineoplasicos
BR0109931A (pt) Composições farmacêuticas
DE50005515D1 (de) Mechanisch stabile pharmazeutische darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive substanzen
ES2185179T3 (es) Preparacion de composiciones farmaceuticas.
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
BR122012014331A8 (pt) Formulações farmacêuticas
BR9810729A (pt) Composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsionante
HUP0204137A2 (hu) Fulvesztrantot tartalmazó gyógyászati készítmény
HUP0104255A2 (hu) Inhalációra alkalmas gyógyászati készítmény
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
CY1105437T1 (el) Συνθεσεις πepιεχοντας διφωσφονικα οξεα
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
BRPI0518191A (pt) métodos e composições para reduzir a toxicidade de um composto farmacêutico
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0209320A (pt) ésteres de uridina farmaceuticamente ativos
HUP0302452A2 (hu) Prosztaglandin E1-et tartalmazó topikus gyógyászati készítmények
AR033688A1 (es) Composicion parenteral reconstituible
ES2124477T3 (es) Uso de un fosfato de ascorbilo y tocoferilo para la preparacion de un medicamento para el tratamiento de la pancreatitis.
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
BR0008829A (pt) Inibição sinérgica de replicação viral porhidrocarbonetos de cadeia longa e análogos denucleosìdeos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADO DE A61K 38/00.

Ipc: A61K 47/00 (2009.01), A61K 38/13 (2009.01), A61K 9

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI